TY - JOUR
T1 - Evaluation of correlations of Plasma Levels of Oxytocin, Omentin-1 and Irisin in Diabetic and Non-Diabetic Metabolic Syndrome Patients
T2 - A Cross Sectional Study in Jordan
AU - Kahwaji, Rama
AU - Kasabri, Violet
AU - Bulatova, Nailya
AU - Akour, Amal
AU - Bustanji, Haidar
AU - Khawaja, Nahla
AU - Hyasat, Dana
AU - Zayed, Ayman
AU - Momani, Munther
AU - Bustanji, Yasser
AU - AlHiari, Yusuf
AU - Mashallah, Sundus
AU - Al-Nouaaimi, Mais
PY - 2017
Y1 - 2017
N2 - Metabolic syndrome (Mets) risk factor biomarkers, namely oxytocin (OXT), omentin-1 and irisin, plasma levels were evaluated via colorimetric enzymatic bioassays. A total of 195 Mets patients were recruited from the outpatients' diabetes and endocrinology clinics at the National Center for Diabetes Endocrinology and Genetics. Participants were subdivided according to their fasting glycemia status into either the normoglycemic subjects group (Mets-controls) or dysglycemic subjects group (Metspre/ T2DM). Enrolled recruits in both study arms were BMI (body mass index)-, gender- and agematched. Distinctively in the Mets-pre/T2DM group; mean circulating levels of both OXT (pg/mL) and omentin-1 (ng/mL) were significantly lower but mean irisin plasma levels (ng/mL) were substantially higher (p<0.01 vs. respective Mets-controls'). Markedly, in the total pool of Mets-participants, plasma OXT levels correlated inversely with irisin plasma levels but proportionally with omentin-1 plasma levels; [Spearman correlation coefficient r =-0.377(N=147) for irisin and r = 0.321(N=138) for omentin-1]. Meanwhile, omentin-1 plasma levels correlated inversely (p<0.001) with irisin's [r =-0.309(N=121)]. These findings indicate that like OXT, irisin and omentin-1 can be postulated as surrogate biomarkers and/or putative pharmacologic agents to limit the deleterious effect of chronic subclinical inflammatory process among Mets individuals with glucose profile abnormalities compared to apparently healthy Mets ones.
AB - Metabolic syndrome (Mets) risk factor biomarkers, namely oxytocin (OXT), omentin-1 and irisin, plasma levels were evaluated via colorimetric enzymatic bioassays. A total of 195 Mets patients were recruited from the outpatients' diabetes and endocrinology clinics at the National Center for Diabetes Endocrinology and Genetics. Participants were subdivided according to their fasting glycemia status into either the normoglycemic subjects group (Mets-controls) or dysglycemic subjects group (Metspre/ T2DM). Enrolled recruits in both study arms were BMI (body mass index)-, gender- and agematched. Distinctively in the Mets-pre/T2DM group; mean circulating levels of both OXT (pg/mL) and omentin-1 (ng/mL) were significantly lower but mean irisin plasma levels (ng/mL) were substantially higher (p<0.01 vs. respective Mets-controls'). Markedly, in the total pool of Mets-participants, plasma OXT levels correlated inversely with irisin plasma levels but proportionally with omentin-1 plasma levels; [Spearman correlation coefficient r =-0.377(N=147) for irisin and r = 0.321(N=138) for omentin-1]. Meanwhile, omentin-1 plasma levels correlated inversely (p<0.001) with irisin's [r =-0.309(N=121)]. These findings indicate that like OXT, irisin and omentin-1 can be postulated as surrogate biomarkers and/or putative pharmacologic agents to limit the deleterious effect of chronic subclinical inflammatory process among Mets individuals with glucose profile abnormalities compared to apparently healthy Mets ones.
KW - Irisin
KW - Jordan
KW - Metabolic syndrome
KW - Omentin-1
KW - Oxytocin
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85032798994&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032798994&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85032798994
SN - 0446-9283
VL - 51
SP - 97
EP - 108
JO - Jordan Medical Journal
JF - Jordan Medical Journal
IS - 3
ER -